MME JOCELYNE BENATAR

Rhumatologue

RPPS 10000965821

🇫🇷 Publications académiques françaises (4)

✨ Profil synthétique

IA · 20/05/2026

MME JOCELYNE BENATAR est une rhumatologue qui a publié des travaux de recherche sur divers aspects de la rhumatologie, notamment les essais cliniques et l'épidémiologie. Ses publications sur PubMed couvrent également des revues et des méta-analyses, ainsi que des aspects liés à la santé mentale et à la fatigue. Ces travaux suggèrent une expertise dans la gestion de pathologies rhumatismales complexes.

Expertises présumées

Essais cliniques en rhumatologie
Épidémiologie des maladies rhumatismales
Fatigue chronique
Santé mentale en rhumatologie
Revue systématique et méta-analyse en rhumatologie

Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.

✨ Génération du profil synthétique IA en cours…

Publications académiques en France

Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.

The effect of vericiguat on sudden cardiac death: insights from the VICTOR trial
2026
ArticleEuropean Journal of Heart Failure

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction

The New England journal of medicine · 2024

📚 234 citations🎯 RCR 44.80Top 0% NIH🩺 Clinique

Effects and costs of real-time cardiac telerehabilitation: randomised controlled non-inferiority trial

Heart (British Cardiac Society) · 2019

📚 232 citations🎯 RCR 13.79Top 1% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Objective Compare the effects and costs of remotely monitored exercise-based cardiac telerehabilitation (REMOTE-CR) with centre-based programmes (CBexCR) in adults with coronary heart disease (CHD). Methods Participants were randomised to receive 12 weeks of telerehabilitation or centre-based rehabilitation. REMOTE-CR provided individualised exercise prescription, real-time exercise monitoring/coaching and theory-based behavioural strategies via a bespoke telerehabilitation platform; CBexCR provided individualised exercise prescription and coaching via established rehabilitation clinics. Outcomes assessed at baseline, 12 and/or 24 weeks included maximal oxygen uptake (V̇O2max, primary) modifiable cardiovascular risk factors, exercise adherence, motivation, health-related quality of life and programme delivery, hospital service utilisation and medication costs. The primary hypothesis was a non-inferior between-group difference in V̇O2max at 12 weeks (inferiority margin=−1.25 mL/kg/min); inferiority margins were not set for secondary outcomes. Results 162 participants (mean 61±12.7 years, 86% men) were randomised. V̇O2 max was comparable in both groups at 12 weeks and REMOTE-CR was non-inferior to CBexCR (REMOTE-CR-CBexCR adjusted mean difference (AMD)=0.51 (95% CI −0.97 to 1.98) mL/kg/min, p=0.48). REMOTE-CR participants were less sedentary at 24 weeks (AMD=−61.5 (95% CI −117.8 to −5.3) min/day, p=0.03), while CBexCR participants had smaller waist (AMD=1.71 (95% CI 0.09 to 3.34) cm, p=0.04) and hip circumferences (AMD=1.16 (95% CI 0.06 to 2.27) cm, p=0.04) at 12 weeks. No other between-group differences were detected. Per capita programme delivery (NZD1130/GBP573 vs NZD3466/GBP1758) and medication costs (NZD331/GBP168 vs NZD605/GBP307, p=0.02) were lower for REMOTE-CR. Hospital service utilisation costs were not statistically significantly different (NZD3459/GBP1754 vs NZD5464/GBP2771, p=0.20). Conclusion REMOTE-CR is an effective, cost-efficient alternative delivery model that could—as a complement to existing services—improve overall utilisation rates by increasing reach and satisfying unique participant preferences.

Effects of high and low fat dairy food on cardio-metabolic risk factors: a meta-analysis of randomized studies

PloS one · 2013

📚 117 citations🎯 RCR 4.73Top 8% NIH🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

ImportanceClear guidelines on the health effects of dairy food are important given the high prevalence of obesity, cardiovascular disease and diabetes, and increasing global consumption of dairy food.ObjectiveTo evaluate the effects of increased dairy food on cardio metabolic risk factors.Data SourcesSearches were performed until April 2013 using MEDLINE, Science Direct, Google,Embase, the Cochrane Central Register of Controlled Trials, reference lists of articles, and proceedings of major meetings.Study SelectionRandomized controlled studies with healthy adults randomized to increased dairy food for more than one month without additional interventions.Data Extraction and SynthesisA standard list was used to extract descriptive, methodological and key variables from all eligible studies. If data was not included in the published report corresponding authors were contacted.Results20 studies with 1677 participants with a median duration of dietary change of 26 (IQR 10-39) weeks and mean increase in dairy food intake of 3.6 (SD 0.92) serves/day were included.Increased dairy food intake was associated with a modest weight gain (+0.59, 95% confidence interval 0.34 to 0.84kg, p<0.0001) but no significant change in waist circumference (0.35 , -0.75 to 1.45 cm); insulin resistance (HOMA –IR -0.94 , -1.93 to 0.05 units); fasting glucose (0.87, -0.27 to 2.01 mg/dl); LDL-cholesterol (1.36 ,-2.38 to 5.09 mg/dl); HDL-cholesterol (0.45, -2.13 to 3.04 mg/dl); systolic (-0.13, -1.73 to 1.98 mmHg) and diastolic blood pressure (0.13, -1.73 to 1.98 mmHg) or C-reactive protein (-0.08, -0.63 to 0.48 mg/L). Results were similar for studies with low-fat and whole-fat dairy interventions.LimitationsMost clinical trials were small and of modest quality. .ConclusionIncreasing whole fat and low fat dairy food consumption increases weight but has minor effects on other cardio-metabolic risk factors.Trial Registration ACTRNAustralian New Zealand Clinical Trials Registry ACTRN12613000401752,http://www.anzctr.org.auEthics Approval NumberNTX/10/11/115

Cookies & analyse de trafic

MME JOCELYNE BENATAR

Pourquoi vous devez consulter ce praticien

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (33) — classées par pathologie

Transversal24

Essai clinique6

Épidémiologie & registres1

Revue / méta-analyse1

Revue générale1

Santé mentale / fatigue1

Datasets & protocoles partagés

Partager cette fiche